

14. The agent of claim 12, wherein said LBP comprises murine LBP.
15. The agent of claim 12, wherein said LBP comprises at least one of rabbit or rat LBP.
16. The agent of claim 12 wherein said LBP comprises hybrid proteins of LBP with the LPS binding site of the bactericidal/permeability increasing protein (BPI) or LBP with the LPS binding site of the limulus anti-LPS factor (LALF).
17. The agent of claim 12 containing point-mutated variants the functions of which are improved at the LPS binding site (amino acids 91-101) by individual exchanges of amino acids.
18. A process for producing the agent of claim 12, which comprises expressing LBP in the baculovirus and in CHO cells, first of all, as fusion protein, and then purifying by separating by the participant in the fusion.
19. A process for treating septicemia caused by gram-negative bacteria which comprises administering to a patient in need thereof the agent of claim 12.
20. The process of claim 19, wherein the septicemia is caused by gram-positive bacteria.
21. A process for treating systemic inflammatory response syndrome caused by trauma and injury, in need thereof the agent of claim 12.